Linked Life Data

1751782

Source:http://linkedlifedata.com/resource/pubmed/id/1751782

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1992-1-27
pubmed:abstractText
The use of the severe combined immunodeficient mouse (SCID), CB-17/Icr//Imd-SCID, was investigated for the production of human hybridoma ascites containing human antibody. Human-human hybridomas, generated from the fusion of lymphocytes isolated from regional draining lymph nodes of cancer patients with the SHFP-1 fusion partner, were injected i.p. at various cell concentrations into pristane-primed SCID mice. Ascites growth was typically observed at 7-14 days postinoculation. No significant differences in ascites yield or production were observed between IgG- and IgM-secreting hybridomas. Yields of immunoreactive human immunoglobulin ranged from approximately 0.5 to 3 mg/ml of harvested ascites. The ease and relatively low cost suggest that the use of SCID mice is preferred over conventional and costly large-scale industrial procedures.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0956-960X
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
190-3
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Use of severe combined immunodeficient (SCID) mice to produce human hybridoma ascites.
pubmed:affiliation
Sci-Clone, Inc., San Diego, CA 92126.
pubmed:publicationType
Journal Article